Pro PG receives S19A for RoActemra (tocilizumab) Vials
Updated: Aug 28
Historical supply notice: This article relates to a previous medicine shortage or regulatory approval. Availability and regulatory status may have changed. Healthcare professionals should contact Pro Pharmaceuticals Group to confirm the current supply position.
For current Australian shortage and supply information, see medicine shortages in Australia.
Pro Pharmaceuticals Group has arranged for the supply of the following overseas registered tocilizumab products on a temporary basis:
RoActemra tocilizumab 80 mg/4 mL concentrate for solution for infusion (Roche Germany)
RoActemra tocilizumab 200 mg/10mL concentrate for solution for infusion (Roche Germany)
RoActemra tocilizumab 400 mg/20mL concentrate for solution for infusion (Roche Germany)
These products are NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 28 February 2022 We also supply RoActemra pre-filled syringes and pens under a separate S19A approval.
Please contact us for more information
